GSK plc

GSK plc ROE

The Return on Equity (ROE) of GSK plc (GSK.L) as of Nov 2, 2026 is 34.90 %. In the previous year, Return on Equity (ROE) was 18.84 % — a change of 85.30% (higher).

ROE

34.90 %

YoY

85.30%

Last updated:

In 2025, GSK plc's return on equity (ROE) was 34.90 %, a 85.30% increase from the 18.84 % ROE in the previous year.

The GSK plc ROE history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

ROE
Date
ROE
Jan 1, 2018
95.82 GBP
Jan 1, 2019
40.73 GBP
Jan 1, 2020
39.41 GBP
Jan 1, 2021
29.13 GBP
Jan 1, 2022
141.12 GBP
Jan 1, 2023
36.92 GBP
Jan 1, 2024
18.84 GBP
Jan 1, 2025
34.90 GBP
The GSK plc ROE history
YEARROEYoY
34.90 %+85.30%
18.84 %-48.99%
36.92 %-73.84%
141.12 %+384.51%
29.13 %-26.10%
39.41 %-3.23%
40.73 %-57.50%
95.82 %-104.25%
-2,252.94 %-2,876.65%
81.14 %-50.73%
164.69 %+154.74%
64.65 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

GSK plc Stock analysis

What does GSK plc do? GSK plc generates revenue through its Pharmaceuticals and Vaccines segments, which focus on developing and selling prescription medicines and vaccines. The Pharmaceuticals segment offers products in Respiratory, HIV, Specialty, and Classic and Established categories, targeting acute and chronic diseases. The Vaccines segment provides over 40 vaccines for pediatric, adolescent, adult, and older populations, including travel vaccines. Customers include healthcare providers, hospitals, and consumers purchasing over-the-counter products. GSK's brand portfolio spans prescription medicines like those for Respiratory and HIV, alongside vaccines such as those for pediatric and adult health. The company's research focuses on six therapeutic areas: Respiratory diseases, HIV/infectious diseases, Vaccines, Immuno-inflammation, Oncology, and Rare diseases. This research drives product development for both segments, ensuring a steady pipeline of medicines and vaccines. The company's products are distributed globally, with the Pharmaceuticals business targeting healthcare professionals and the Vaccines business serving public health programs and individual consumers. GSK's strategy emphasizes innovation in key therapeutic areas to address unmet medical needs, leveraging its extensive research and development capabilities to maintain market leadership. GSK plc is one of the most popular companies on Eulerpool.

ROE Details

Decoding GSK plc's Return on Equity (ROE)

GSK plc's Return on Equity (ROE) is a fundamental metric evaluating the company's profitability relative to its equity. Calculated by dividing net income by shareholder's equity, ROE illustrates how effectively the company is generating profits from shareholders’ investments. A higher ROE represents enhanced efficiency and profitability.

Year-to-Year Comparison

Analyzing GSK plc's ROE on a yearly basis aids in tracking its profitability trends and financial performance. An increasing ROE suggests enhanced profitability and value generation for shareholders, whereas a declining ROE may indicate issues in profit generation or equity management.

Impact on Investments

GSK plc's ROE is instrumental for investors assessing the company's profitability, efficiency, and investment attractiveness. A robust ROE indicates the firm’s adeptness at converting equity investments into profits, thereby enhancing its appeal to potential and current investors.

Interpreting ROE Fluctuations

Changes in GSK plc’s ROE can emanate from variations in net income, equity capital, or both. These fluctuations are scrutinized to evaluate management’s effectiveness, financial strategies, and the inherent risks and opportunities, aiding investors in making informed decisions.

Frequently Asked Questions about GSK plc stock

Return on Equity (ROE) of GSK plc is 34.90 % in 2025.

Return on Equity (ROE) of GSK plc changed from 18.84 % to 34.90 %, representing a 85.30% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Return on Equity (ROE) GSK plc since 2006 – with annual values, charts, and detailed analysis.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Return on Equity (ROE)'s GSK plc with sector peers and the industry average to assess whether it is attractive.

To evaluate Return on Equity (ROE)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Return on Equity (ROE).

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Profitability — GSK plc

All Key Metrics — GSK plc